Cullinan Therapeutics, Inc.

Aug 19, 2026

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

The Phase 3 REZILIENT3 trial results for Zipalertinib plus chemotherapy have been selected for presentation at the IASLC 2026 World Conference on Lung Cancer. The trial successfully met its primary endpoint of progression-free survival in patients with EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC). This presentation highlights the significance of the findings in the context of first-line treatment options.

Aug 12, 2026

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial has successfully met its primary endpoint of progression-free survival. This trial evaluates the efficacy of zipalertinib in combination with chemotherapy for patients with EGFR Exon 20 insertion mutation non-small cell lung cancer. The results from this interim analysis are promising for future treatment options.

Aug 6, 2026

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Cullinan Therapeutics provided a corporate update highlighting promising data for its T cell engagers CLN-978 and velinotamig, with plans for Phase 2 studies in 2027. The company reported a net loss of $53.7 million for Q2 2026 but maintains a strong cash position of $356 million, ensuring operational runway into 2029. Upcoming data presentations are expected to further inform the clinical potential of their therapies.

Jul 28, 2026

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Cullinan Therapeutics announced positive feedback from the FDA regarding its CLN-049 program during an End-of-Phase 1 meeting. The company plans to initiate a potentially registrational Phase 2 study for CLN-049 in patients with relapsed/refractory acute myeloid leukemia (AML) in Q3 2026. The FDA's feedback supports the development strategy and highlights the urgent need for new treatments in this area.

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Cullinan Therapeutics has reported promising clinical data for its T cell engager programs, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data indicates significant efficacy, including clinical remissions and renal responses in patients. The company plans to expand its clinical trials and present further data in the coming months.

Jun 6, 2026

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and

Cullinan Therapeutics presented initial clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress. The data indicates significant clinical benefits, including remissions in patients with systemic lupus erythematosus and rheumatoid arthritis following treatment. Alongside a favorable safety profile and substantial B cell depletion, the data support CLN-978’s potential as a novel therapeutic option. Further studies are planned to advance the development of CLN-978 for these challenging-to-treat autoimmune conditions.

May 26, 2026

▲ +11.7%on this news

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics will host an Immunology Day event on June 10, 2026, in New York City to present new clinical data for its autoimmune disease therapies, CLN-978 and Velinotamig. Initial results from over 30 patients involved in systemic lupus erythematosus and rheumatoid arthritis studies will be shared. The event is aimed at analysts and institutional investors, featuring discussions led by prominent clinical experts. The company aims to provide insights into data milestones and its global development strategy.

May 19, 2026

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Cullinan Therapeutics has received FDA Orphan Drug Designation for CLN-049, a novel FLT3xCD3 T cell engager, aimed at treating relapsed/refractory acute myeloid leukemia (AML). This designation underscores the urgent need for new therapies in AML, particularly for patients with TP53 mutations. CLN-049 is currently being evaluated in ongoing Phase 1 clinical trials.

May 18, 2026

▼ -5.5%on this newsshared move

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

Cullinan Therapeutics announced the presentation of initial clinical data for CLN-978 at the EULAR 2026 Congress. The data, from ongoing Phase 1 studies, indicates a favorable safety profile and early signs of clinical activity in patients with treatment-refractory rheumatoid arthritis and systemic lupus erythematosus. The findings will be shared in detail during the congress in London.

May 7, 2026

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Cullinan Therapeutics provided a corporate update and reported its Q1 2026 financial results. The company announced initial clinical data for its CD19 T cell engager, CLN-978, to be presented at the EULAR 2026 Congress. Additionally, the FDA accepted the NDA for zipalertinib, with a target action date of February 27, 2027. Cullinan's financial position remains strong, with cash reserves expected to last into 2029.

Apr 28, 2026

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The FDA has accepted a New Drug Application for zipalertinib, a treatment for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. This acceptance is based on positive results from the Phase 2b REZILIENT1 clinical trial, which demonstrated a 35% objective response rate. The PDUFA target action date is set for February 27, 2027.

Mar 10, 2026

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed fo

Cullinan Therapeutics has announced its fourth quarter and full year 2025 financial results alongside several key updates. Initial clinical data for their therapy CLN-978 for systemic lupus erythematosus and rheumatoid arthritis is slated for release in Q2 2026. Furthermore, the company has completed its rolling NDA submission for zipalertinib, with expectations for significant data releases throughout 2026. Despite a growing cash position of $439 million, the company reported increasing net losses and R&D expenses, highlighting both potential progress and financial challenges.

Feb 24, 2026

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company focuses on developing first- or best-in-class therapies for autoimmune diseases and cancer. Webcasts of the events will be available on their investor relations website, showcasing their commitment to innovation in healthcare.

Feb 18, 2026

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

Cullinan Therapeutics will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026. CEO Nadim Ahmed and CMO Jeffrey Jones will represent the company, discussing their innovative approaches in developing therapies for autoimmune diseases and cancer. A webcast of the event will be available on their investor relations website.

Feb 5, 2026

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

Cullinan Therapeutics will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. CEO Nadim Ahmed and CMO Jeffrey Jones will represent the company during the event. A webcast of the chat will be available on the company's investor relations website.

Jan 8, 2026

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Dec 31, 2025

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data C

Cullinan Therapeutics has announced significant corporate updates, highlighting anticipated milestones for 2026, including multiple data readouts for their drug CLN-978 across autoimmune diseases. The company is also advancing its CLN-049 program and preparing for a rolling NDA submission for zipalertinib by the first quarter of 2026. With a strong cash position projected to last into 2029, Cullinan is strategically positioned to accelerate its development programs further. The successful execution of these plans is critical for their future growth.

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

Cullinan Therapeutics presented promising clinical data for CLN-049, a novel FLT3xCD3 T cell engager, at the 67th ASH Meeting. The Phase 1 study showed a 31% complete response rate in heavily pretreated patients with relapsed/refractory acute myeloid leukemia (AML). The drug has received Fast Track designation from the FDA, indicating its potential to improve treatment options for AML patients.

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Cullinan Therapeutics has received FDA Fast Track designation for CLN-049, a novel T cell engager aimed at treating relapsed/refractory acute myeloid leukemia (AML). Initial Phase 1 trial results indicate meaningful efficacy, including complete responses in heavily pre-treated patients. The designation underscores the urgent need for new treatment options in this patient population.

Nov 20, 2025

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Nov 10, 2025

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Cullinan Therapeutics, Inc. announced its participation in two investor conferences and plans to host an event at the 2025 ASH Annual Meeting in Orlando, FL. The company aims to showcase its advancements in developing therapies for autoimmune diseases and cancer. Webcasts of these events will be available on their investor relations website.

Nov 6, 2025

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Cullinan Therapeutics announced promising Phase 1 data for CLN-049, showing a ~30% complete response rate in relapsed/refractory AML patients. The company plans to present this data at the ASH 2025 Annual Meeting. Additionally, initial data for CLN-978 in autoimmune diseases is expected in 2026. However, the company has discontinued the CLN-619 and CLN-617 programs.

Nov 3, 2025

▼ -9.8%on this newsshared move

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Cullinan Therapeutics announced new data for CLN-049, a bispecific T cell engager, showing significant anti-leukemic activity in patients with relapsed/refractory acute myeloid leukemia (AML). The Phase 1 study reported a 31% composite complete response rate and a manageable safety profile. The findings will be presented at the 67th ASH Annual Meeting on December 8, 2025.

Oct 25, 2025

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Cullinan Therapeutics presented new preclinical data for CLN-978 at ACR Convergence 2025, showcasing its ability to deplete B cells in various autoimmune diseases. The data indicates significant efficacy in both in vitro and in vivo models, suggesting potential therapeutic benefits for patients with rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus. The company is advancing clinical trials globally across these indications.

Oct 12, 2025

▲ +5.8%on this news· ran to +18% by day 3

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Sep 12, 2025

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Cullinan Therapeutics, Inc. will have its Chief Medical Officer, Jeffrey Jones, participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 16, 2025. This event underscores the company's focus on developing targeted therapies for autoimmune diseases and cancer. A webcast of the chat will be available on their investor relations website.

Sep 9, 2025

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Sep 4, 2025

▼ -10.5%on this newsshared move

CORPORATE OVERVIEW September 2025 Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other th

Cullinan Oncology provides a corporate overview detailing its strategic plans and financial health as of September 2025. The company has a strong cash position of $511 million, which is expected to support operations until 2028, while presenting multiple product candidates with first-in-class potential targeting autoimmune diseases. Key clinical trials are ongoing, and initial data for some candidates will be released in 2026. However, significant risks remain, including regulatory challenges and uncertainties that may affect the outcomes of clinical studies.

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis

Cullinan Therapeutics has reported its corporate update and financial results for Q2 2025, indicating advancements in its CLN-978 program, now enrolling Phase 1 studies in various autoimmune diseases. The company has also in-licensed the BCMA-directed bispecific T cell engager, velinotamig, as part of its expansion in targeted therapies. Financially, while the company holds a strong cash position of $510.9 million, it reported a net loss increase, raising concerns about operational expenses. New board appointments aim to strengthen the company's strategic capabilities.

Jul 22, 2025

▲ +7.8%on this news

Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Jun 4, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Cullinan Therapeutics has licensed velinotamig, a bispecific T cell engager, from Genrix Bio for the treatment of autoimmune diseases. This agreement enhances Cullinan's portfolio and allows for the development of a promising therapy that has shown efficacy in multiple myeloma. The company plans to leverage data from an upcoming Phase 1 study in China to accelerate global development.

May 29, 2025

▲ +10.7%on this news

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

Cullinan Therapeutics will host an analyst and investor event at the 2025 ASCO Annual Meeting and participate in the Jefferies 2025 Global Healthcare Conference. The events will showcase the company's commitment to developing targeted therapies for cancer and autoimmune diseases. Webcasts of these events will be available on their investor relations website.

May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology announced positive results from the Phase 2b REZILIENT1 trial of zipalertinib for patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The results will be presented at the ASCO Annual Meeting on June 1, 2025. Zipalertinib demonstrated efficacy and a manageable safety profile in this patient population.

May 8, 2025

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rhe

Cullinan Therapeutics announced a corporate update along with its first quarter 2025 financial results. The company has received approval from the European Medicines Agency for its drug CLN-978, paving the way for Phase 1 trials in rheumatoid arthritis and Sjögren's disease. Additionally, positive results from the REZILIENT1 study of zipalertinib were highlighted, with plans to present them at the 2025 ASCO Annual Meeting. However, the company reported an increase in net loss and the discontinuation of CLN-619 for certain cancer treatments.

Apr 23, 2025

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Cullinan Therapeutics announced that results from its REZILIENT1 study of zipalertinib will be presented at the 2025 ASCO Annual Meeting. The study focuses on patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who have received prior treatment. These findings aim to showcase the drug's efficacy and safety in a patient population with limited treatment options. Cullinan's management will discuss the results at a corresponding investor event during the conference.

Apr 16, 2025

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Feb 27, 2025

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in

Cullinan Therapeutics has provided a corporate update detailing financial results for Q4 and full-year 2024, revealing significant cash reserves of $606.9 million. The company anticipates initial clinical data from a Phase 1 study of CLN-978 in systemic lupus erythematosus by Q4 2025 and reports that the pivotal Phase 2b study of zipalertinib has met its primary endpoint. While the financial report shows an increased net loss compared to previous years, the overall outlook remains optimistic due to upcoming clinical milestones.

Jan 30, 2025

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Cullinan Therapeutics, Inc. announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference. The conference is slated to occur in New York on February 5 and 6, 2025. The discussion will be accessible via a webcast on the company's investor relations website.

Jan 28, 2025

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who H

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced that their Phase 2b trial of zipalertinib met its primary endpoint, showcasing significant efficacy in treating patients with NSCLC harboring EGFR exon 20 insertion mutations. The trial's favorable safety profile is consistent with previous studies, and full results are expected to be presented soon. The companies plan to submit for U.S. regulatory approval later in 2025, following discussions with the FDA.

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan Therapeutics announced new preclinical data for CLN-978, a CD19-directed T cell engager, demonstrating its efficacy in activating T cells and depleting B cells in patients with autoimmune conditions. These findings will be presented at ACR Convergence 2024, alongside details of a global Phase 1b study focusing on systemic lupus erythematosus. The company has received regulatory clearance for clinical trials in both the U.S. and Australia, with initial clinical data expected by late 2025.

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial cl

Cullinan Therapeutics provided updates on its clinical development programs and financial results for Q3 2024, highlighting progress in multiple areas. The company received regulatory clearance for initiating a global Phase 1 study for CLN-978 in systemic lupus erythematosus (SLE) and expects to present initial data in Q4 2025. Furthermore, Zipalertinib's pivotal Phase 2b study enrollment was completed ahead of schedule, with results anticipated by mid-2025. Despite these advancements, Cullinan reported a net loss increase and higher R&D and G&A expenses compared to the previous year.

Nov 5, 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics, Inc. announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York. The event is scheduled for November 19, 2024, at 1:50 p.m. ET. A webcast will be available for those unable to attend the event in person, reinforcing Cullinan's commitment to transparency with investors.

Nov 4, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics announced the upcoming presentation of preclinical data for CLN-978, a novel bispecific T cell engager, at ACR Convergence 2024. The data suggest that CLN-978 is a highly potent therapy capable of depleting B cells, with potential applications in treating autoimmune diseases. The company has secured FDA clearance for a global Phase 1 clinical trial aimed at evaluating CLN-978 for systemic lupus erythematosus. The presentation will take place on November 16, 2024, in Washington, D.C.

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus CLN-978 is the first deve

Cullinan Therapeutics has received U.S. FDA clearance for its Investigational New Drug application for CLN-978, marking a significant step in addressing systemic lupus erythematosus (SLE). This bispecific T cell engager is notably the first to gain IND clearance for autoimmune diseases and will enter a Phase 1 clinical trial focused on patients with moderate to severe symptoms. The trial aims to evaluate the drug's safety and efficacy, potentially providing a new treatment option for patients with unmet medical needs in SLE care.

Sep 17, 2024

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus Phase 1 clinical trial is designed to assess the safety, pharmacokinetics

Cullinan Therapeutics has received approval to start a global Phase 1 clinical trial of CLN-978, a bispecific T cell engager designed for systemic lupus erythematosus treatment. The trial, sanctioned by the Human Research Ethics Committee in Australia, will assess the safety and pharmacokinetics of CLN-978 across multiple international sites. This investigational candidate offers the promise of a convenient treatment option aimed at improving the lives of patients suffering from SLE, an autoimmune disease affecting approximately 430,000 individuals worldwide.

Sep 16, 2024

▼ -5.7%on this newsshared move

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics submitted an Investigational New Drug application to the FDA for CLN-978, aimed at treating systemic lupus erythematosus (SLE). The bispecific T cell engager is designed to target CD19-expressing cells and could provide a disease-modifying treatment option for the approximately 160,000 people affected by SLE in the U.S. Currently, available treatments do not typically induce treatment-free remission, making this new approach significant. The company is focused on advancing its clinical studies to bring CLN-978 to patients.

Sep 14, 2024

▼ -5.7%on this newsshared move

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Cullinan Therapeutics presented updated data from the Phase 2b study of zipalertinib for patients with non-small cell lung cancer having EGFR exon 20 insertion mutations, revealing an objective response rate of 40%. With 45 participants enrolled, results showed that zipalertinib maintained a consistent safety profile, with the majority of adverse events being mild. The trial has been completed ahead of schedule, showcasing a strong commitment to advancing the drug in a setting with significant unmet needs. The findings were shared at the European Society for Medical Oncology Congress 2024.

Aug 8, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed

Cullinan Therapeutics has reported a positive corporate update and the financial results for Q2 2024. The company is preparing to file an IND application for its drug CLN-978 aimed at treating systemic lupus erythematosus by the third quarter of 2024 and is also pursuing rheumatoid arthritis as a second indication. Recent data on CLN-619 at the ASCO meeting indicated its effectiveness in treating certain lung cancers. Additionally, the company continues to manage its financial standing and has appointed a new board member to strengthen its growth strategy.

Jun 1, 2024

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCL

Cullinan Therapeutics announced positive initial data from its pivotal Phase 2b REZILIENT1 study of zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations. The study reported a 39% objective response rate and a manageable safety profile, with no severe treatment-related adverse events. This represents the first systematic clinical data on zipalertinib following amivantamab treatment, indicating the potential of zipalertinib in a challenging patient population. The company is on track to complete enrollment in the trial by the end of 2024.

May 24, 2024

▲ +6.5%on this news

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics, a biopharmaceutical company, will have its CEO Nadim Ahmed and CMO Jeffrey Jones participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit. The event takes place on May 28 and 29, 2024, and will feature a discussion that may provide insights into the company's innovations. The chat is accessible through a webcast on the company's investor relations website. This engagement underlines Cullinan's focus on developing targeted therapies in the oncology field.

May 23, 2024

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 Preliminary data from CLN-619 in combination wit

Cullinan Therapeutics announced promising preliminary data for CLN-619, a novel anti-MICA/B antibody, in combination with pembrolizumab, showing objective responses in patients with previously resistant tumor types such as non-small cell lung cancer. The clinical trial results will be presented at the ASCO 2024 Annual Meeting. Additionally, longer-term follow-up indicated a durable clinical benefit from CLN-619 monotherapy. Based on initial clinical activity, Cullinan is expanding its study to include additional cohorts in NSCLC.

May 15, 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 A

Cullinan Therapeutics has provided a corporate update and reported its financial results for Q1 2024. The company is set to present data for its solid tumor treatment CLN-619 at the upcoming ASCO 2024 meeting, and it has shifted the focus of CLN-978 towards autoimmune diseases like systemic lupus erythematosus. Financially, Cullinan has a strong cash position of $434.8 million, bolstered by a recent $280 million private placement, expected to fund operations through 2028. While the company celebrates progress in its drug development pipeline, it also faces a notable net loss and regulatory uncertainties.

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Cullinan Therapeutics has appointed Mary Kay Fenton as its new Chief Financial Officer, effective April 29, 2024. CEO Nadim Ahmed expressed optimism about Fenton's experience and strategic capabilities, especially as the company focuses on expanding into autoimmune diseases. Fenton has a rich background in the biotechnology sector, holding significant roles in various companies and managing critical transactions, which positions her to enhance Cullinan's growth during this pivotal time.

Apr 24, 2024

▲ +13.3%on this news· ran to +63% by day 3shared move

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will present results from its Phase 1 trial of CLN-619, a novel anti-MICA/B antibody, at the 2024 ASCO Annual Meeting. The data will highlight findings from both monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors. The presentation is scheduled for June 1, 2024, and represents an important step in evaluating the therapeutic potential of CLN-619 in oncology.

Apr 16, 2024

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Cullinan Therapeutics has announced a strategic shift to focus on autoimmune diseases, specifically developing its novel therapy CLN-978 to target systemic lupus erythematosus as its initial indication. This follows promising clinical observations from its previous studies, demonstrating the potential of CLN-978 in depleting B cells effectively. The company has also secured $280 million in financing to support its new direction and has undergone a corporate name change to reflect its broader therapeutic ambitions. A virtual investor event is scheduled to discuss these updates further.

Apr 16, 2024

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are

Cullinan Therapeutics announced an oversubscribed private placement financing of approximately $280 million from institutional investors. The funds will be used to support ongoing research and development efforts, specifically targeting the CD19xCD3 T cell engager clinical program for autoimmune diseases. This financing is anticipated to extend the company's cash runway into 2028. The deal is expected to close on or about April 18, 2024, subject to customary conditions.

Mar 14, 2024

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarte

Cullinan Oncology has provided a corporate update alongside its financial results for Q4 and the full year 2023. The company is set to unveil additional data for its lead candidate, CLN-619, in solid tumors, and has secured FDA clearance to evaluate CLN-619 in relapsed/refractory multiple myeloma. Despite a strong cash position of $468.3 million, the company announced a significant net loss for the year and the departure of its CFO. Cullinan continues to develop its promising pipeline with plans for multiple data presentations throughout 2024.

Mar 1, 2024

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Cullinan Oncology announced that the FDA has cleared its IND application for CLN-619, a novel MICA/B antibody targeting relapsed/refractory multiple myeloma. This marks the initiation of the first clinical study of a MICA/B antibody in hematologic malignancies. The company is also conducting ongoing trials for CLN-619 in solid tumors with results expected in Q2 2024. The trial aims to enhance immune recognition of tumor cells by restoring MICA/B expression, which could address significant unmet clinical needs in treating multiple myeloma.

Feb 27, 2024

Cullinan Oncology to Participate in Upcoming Investor Conferences

Cullinan Oncology, Inc. (CGEM) has announced its participation in two upcoming investor conferences. The Chief Medical Officer will speak on a panel discussing gynecologic cancers at the TD Cowen Annual Health Care Conference in Boston on March 5, 2024. The Chief Financial Officer will also participate in a fireside chat at the Leerink Partners Global Biopharma Conference in Miami on March 13, 2024. These events will provide a platform for the company to showcase its advancements in oncology therapeutics.

Dec 18, 2023

▲ +10.8%on this news

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cullinan Oncology, Inc. (Nasdaq: CGEM) has announced that CEO Nadim Ahmed will deliver a presentation at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 11, 2024. This conference is notable for bringing together key players in the biopharmaceutical industry. The presentation aims to showcase the company's advancements in targeted oncology therapies. A live webcast of the presentation will be available for those unable to attend in person.

Dec 14, 2023

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology has announced the dosing of the first patient in a Phase 1 clinical trial for CLN-617, a novel cytokine therapy that combines IL-2 and IL-12. This trial aims to assess the safety, pharmacokinetics, and preliminary efficacy of CLN-617, both alone and in combination with the checkpoint inhibitor pembrolizumab, for patients with advanced solid tumors. The innovative design of CLN-617 seeks to enhance local delivery and retention within tumors, potentially generating broader immune responses and improving treatment outcomes. This marks a significant step in Cullinan's clinical development of targeted oncology therapies.

Nov 8, 2023

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phas

Cullinan Oncology provided a corporate update and reported its financial results for Q3 2023, highlighting advances in its pipeline, including the ongoing development of oncology therapies CLN-619 and zipalertinib. The company reported a cash position of $482 million, extending its financial runway into the second half of 2026. Despite a higher net loss of $39.2 million in Q3, Cullinan anticipates significant clinical data updates throughout 2024, showcasing their emphasis on innovation in oncology treatment.

Nov 3, 2023

▲ +5.5%on this newsshared move

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Cullinan Oncology announced the acceptance of five abstracts for presentation at the SITC 2023 Annual Meeting, highlighting data from their immunotherapy pipeline. Key focus areas include CLN-619, which demonstrated clinical activity in tumors typically resistant to therapies, as well as data on other innovative candidates like CLN-418 and CLN-978. The presentations underscore Cullinan's commitment to advancing targeted cancer therapies and emphasize ongoing clinical trials evaluating each investigational agent. This event marks a significant opportunity for Cullinan to share their advancements with the oncology community.

Oct 10, 2023

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology announced positive interim data from its Phase 1/2a trial of CLN-081, an EGFR inhibitor for NSCLC patients with exon 20 mutations. The trial showed a confirmed objective response rate of 46% at the 100 mg BID dose, with an acceptable safety profile. The company has initiated a Phase 2a expansion cohort to further evaluate the drug's efficacy.

Aug 10, 2023

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZIL

Cullinan Oncology has provided a comprehensive update on its financial results and clinical developments. The company announced the opening of the REZILIENT-3 Phase 3 study for zipalertinib in patients with EGFR exon 20 insertion mutation non-small-cell lung cancer. Additionally, promising initial data for CLN-619 from the ASCO 2023 meeting was highlighted, alongside the dosing of the first patient in a Phase 1 study for CLN-978 in relapsed/refractory B cell non-Hodgkin lymphoma. Despite a net loss of $32.2 million in Q2 2023, Cullinan maintains a significant cash position to support its ongoing operations and initiatives.

Aug 9, 2023

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Cullinan Oncology has initiated a Phase 1 clinical trial for CLN-978, a novel CD19xCD3 T cell engager, aimed at treating relapsed/refractory B-Cell Non-Hodgkin Lymphoma. This open-label trial will evaluate the safety, tolerability, and preliminary efficacy of the drug in patients without approved standard therapies. The administration of CLN-978 subcutaneously may improve patient experience and reduce toxicity while potentially offering new therapeutic options for B-NHL and other B cell malignancies.

May 25, 2023

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose ca

Cullinan Oncology announced the first clinical data for its anti-MICA/B antibody, CLN-619, showcasing promising monotherapy activity across different solid tumors, including those resistant to checkpoint inhibitors. The Phase 1 study, set to be presented at ASCO 2023, indicates a favorable safety profile and encourages further development, particularly in gynecological cancers. Following the initial efficacy observations, Cullinan intends to expand its study cohorts to include endometrial and cervical cancers, aiming to address significant unmet medical needs in these areas.

May 11, 2023

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results Zipalertinib pivotal trial now enrolling at the 100mg BID dose only First clinical data for CLN-049 and CLN-619 to be reported

Cullinan Oncology has provided a corporate update and announced its first quarter 2023 financial results, highlighting key advancements in its pipeline, including the Zipalertinib pivotal trial now enrolling at the 100mg BID dose. The company is set to present preliminary data for CLN-049 and clinical data for CLN-619 at upcoming conferences. With a strong cash position of $503.5 million, Cullinan anticipates that 2023 will be a transformational year. However, the company posted a net loss of $58.1 million, indicating ongoing financial challenges.

Apr 26, 2023

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

Apr 20, 2023

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

Cullinan Oncology, Inc. will participate in Stifel's 2023 Targeted Oncology Days on April 26, 2023, where CEO Nadim Ahmed will engage in a fireside chat. This event aims to facilitate direct interaction between the company's management and investors. A live webcast will be available for those interested in the discussion. Cullinan Oncology is dedicated to developing innovative treatments for cancer, utilizing a diverse pipeline and partnerships in the field.

Mar 27, 2023

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Cullinan Oncology has announced that the U.S. FDA has cleared its Investigational New Drug application for CLN-617, a novel fusion protein combining IL-2 and IL-12 cytokines. The company plans to initiate a Phase 1 trial to evaluate the safety and efficacy of CLN-617 in patients with advanced solid tumors. Preclinical data suggests that the therapy can evoke a broad immune response and might be particularly effective when used alongside checkpoint inhibitors. This advancement marks Cullinan's sixth clinical-stage asset aimed at enhancing cancer treatment standards.

Mar 14, 2023

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

Mar 9, 2023

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Expanded clinical stage portfolio through licensing of U.S. rights to CLN-418 Received FDA clearance of IND appl

Cullinan Oncology reported a corporate update highlighting significant developments in their clinical pipeline and fourth quarter 2022 financial results. The company expanded its portfolio by licensing U.S. rights for CLN-418 and received FDA clearance for the IND application of CLN-978. The outlook includes the expectation of having six active clinical programs by the end of 2023 and a cash runway extending into 2026. However, they also reported a net loss for the fourth quarter, emphasizing the challenges of sustaining operations amidst significant ongoing development efforts.

Feb 27, 2023

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

Cullinan Oncology, Inc. will participate in Cowen's 43rd Annual Health Care Conference, with CEO Nadim Ahmed scheduled to present on March 6, 2023. A live webcast of the presentation will be accessible on the company's investor relations website. Cullinan Oncology focuses on developing targeted therapies for cancer and seeks to establish new standards of care in the oncology space. The event presents an opportunity for investor engagement and highlights the company's pipeline of innovative therapies.

Feb 13, 2023

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

Cullinan Oncology has secured an exclusive license for HBM7008, a bispecific immune activator intended for treating solid tumors, from Harbour BioMed. This deal allows Cullinan to develop and commercialize the product within the U.S., adding it to a growing portfolio of clinical-stage assets. With a lucrative upfront payment and potential milestone earnouts, this partnership exemplifies Cullinan's strategy to enhance its oncology pipeline and capitalize on innovative therapeutic approaches.

Feb 2, 2023

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

Cullinan Oncology, Inc. (Nasdaq: CGEM) announced participation in two important conferences in February 2023: Guggenheim's 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference. CEO Nadim Ahmed will engage in fireside chats at these events, enhancing the company's visibility in the oncology field. Live webcasts of these discussions will be available on the company's investor relations website. The participation underscores Cullinan's commitment to advancing cancer treatment through innovative therapies.

Feb 1, 2023

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology, Inc. (Nasdaq: CGEM) has announced the grant of stock options totaling 56,000 shares to three new employees as part of its recruitment efforts. These options were issued outside of the company's existing stock option plan, in compliance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $11.58 and will vest over four years, with the first installment vesting on the one-year anniversary of their grant date. This move reflects Cullinan's strategic initiatives to attract talent as it continues to develop its oncology pipeline.

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Cullinan Oncology has received clearance from the U.S. FDA for its Investigational New Drug application for CLN-978, a novel T-cell engager targeting relapsed/refractory B-cell non-Hodgkin lymphoma. This marks a significant advancement in their clinical portfolio as they prepare to launch a Phase 1 trial to assess CLN-978's safety and efficacy. The drug is designed to bind with high affinity to CD19, enhancing clinical efficacy even at low expression levels. CLN-978 aims to provide a convenient treatment option with subcutaneous delivery and reduced toxicity for patients with B-cell malignancies.

Nov 14, 2022

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92% Continued enrollment in CLN

Nov 2, 2022

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 Cullinan increases ownership in MICA subsidiary from 54% t

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 Cullinan increases ownership in MICA subsidiary from 54% to 92% through share purchase from existing financial inve

Sep 7, 2022

▲ +5.4%on this news

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management will

Aug 15, 2022

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today

Aug 10, 2022

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Present

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data for CLN-081 at the 100mg BID

Aug 1, 2022

Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Offic

Jul 5, 2022

Cullinan Oncology to Participate in William Blair Biotech Focus Conference

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Scientific Officer, Patr

Jun 27, 2022

UNAUDITED PRO FORMA FINANCIAL INFORMATION On June 21 , 2022, Cullinan Oncology, Inc. ( Cullinan ) completed the previously announced sale of its equity interests in Cullinan Pearl Corp. ( Cullinan Pearl ) to Taiho Pharma

UNAUDITED PRO FORMA FINANCIAL INFORMATION On June 21, 2022, Cullinan Oncology, Inc. ( Cullinan ) completed the previously announced sale of its equity interests in Cullinan Pearl Corp. ( Cullinan Pearl ) to Taiho Pharmaceutical Co., Ltd. ( Taiho Pharma ) pursuant to the terms o

Jun 23, 2022

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

May 31, 2022

▼ -6.9%on this newsshared move

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

May 26, 2022

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patien

May 19, 2022

▼ -5%on this news

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff T

May 16, 2022

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data ac

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data accepted for oral presentation at the American Society for C

May 12, 2022

▲ +23.1%on this news· ran to +65% by day 3shared move

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho s Acquisition of Cullinan Pearl Taiho obtains exclusive global rights to CLN-081/

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho s Acquisition of Cullinan Pearl Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullina

Apr 27, 2022

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced the presentation of updated clinical re

Apr 5, 2022

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its management team will particip

Mar 28, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and tolerability profile observed in heavily pre-treated patients Pivotal study initiation expected 2H 2022 following food effect study CAMBRIDGE, Mass., March 28, 2022 (GLOBE NE

Mar 17, 2022

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 202

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022 CLN-049 and CLN-619 patient dosing initiated in Decembe

Mar 17, 2022

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, will provide a regulatory update on CLN-081 during a webin

Mar 9, 2022

▲ +8.9%on this news

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will be participating in the Barcl

Mar 8, 2022

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022

Feb 28, 2022

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Jeffrey (Jeff) Jones, M.D., MPH,

Feb 7, 2022

▲ +6.5%on this news

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink’s 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022. Nadim Ahmed, Cullinan’s Chi

Jan 10, 2022

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a bi

Jan 5, 2022

▼ -6.7%on this newsshared move

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in January: 40th Annual J.P. Morgan Healthcare Conference Thursday, January 13 at 7:30 a.

Dec 16, 2021

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued hig

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose Continued high response rate with favorable safety and tolerability profile observe

Dec 13, 2021

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will provide a clinical update on CLN-081 during a webinar on Thursday, December 16

Nov 22, 2021

Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, today announced that it will be participating in the 4th Annual Evercore ISI Health

Nov 9, 2021

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021 Cullinan MICA and Cullinan Florentine

Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer Ahmed s appointment brings broad development and operational leadership experience to Cullinan, reflecting the advancement of its pipeline and transition

Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer Ahmed s appointment brings broad development and operational leadership experience to Cullinan, reflecting the advancement of its pipeline and transition to a later-stage oncology company CAMBRIDGE, Mass., Octob

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort IND clearance of two immuno-oncology p

Aug 5, 2021

▲ +13.6%on this newsshared move

Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that it will be participating in the 41st Annual Canaccord Genuity Growth Conference from August 10th to August 12th, 2021. Jeff Trigilio, Cullinan’s Chief Fin

Jun 29, 2021

Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

Jun 7, 2021

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

Jun 4, 2021

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl s CLN-081 in NSCLC EGFR Exon 20 Patients CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity Pr

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl s CLN-081 in NSCLC EGFR Exon 20 Patients Cambridge, MA, June 4, 2021 Cullinan Oncology, Inc. (Nasdaq: CGEM) ( Cullinan ), an oncology company seeking to drive shareholder returns by focusing on the patient,

May 21, 2021

Cullinan Oncology Announces Management Transition

May 19, 2021

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

May 14, 2021

Cullinan Oncology Reports First Quarter 2021 Financial Results Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations

Cullinan Oncology Reports First Quarter 2021 Financial Results Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins Cash, cash equivalents and investments of $473.0 million as of Mar

Apr 7, 2021

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference. Event: Needham Virt

Mar 30, 2021

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional IND

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan

Mar 2, 2021

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executiv

Feb 22, 2021

Cullinan Management, Inc. Announces Business Update

Cullinan Management, Inc. Announces Business Update Cambridge, MA, February 22, 2021 Cullinan Management, Inc. (Nasdaq: CGEM) ( Cullinan ), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announc

Jan 12, 2021

Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 8, 2021